التهاب شبكية الفيروس المضخم للخلايا: ماذا تفعل عندما يفشل سيدوفوفير أو فوسكارنيت في إزالة المستضدات الفيروسية

References

DOI: 10.3390/v16091427

• Letermovir (LET), a CMV-terminase inhibitor preventing viral DNA packaging, is used for drug-resistant CMVR in patients with acute immunodeficiency syndrome.
• The recommended dose of LET for CMV retinitis is 480 mg once daily, continued for up to 100 days post-transplant.
• It can be administered either orally or through an IV infusion over 1 h.
• The recommended dose of MBV is at least 400 mg twice daily, demonstrating similar efficacy to VGCV in clearing CMV viremia among HSCT or SOT.
• Despite this limitation, MBV's resistance profile and oral administration make it a valuable option for treating refractory or drug-resistant CMV infections in transplant recipients.
• Studies indicate that infusing CMV-specific T cells can restore protective immunity.
• Combination therapy with CMVIG and GCV significantly enhance visual outcomes and reduce intraocular CMV viral load in cases of vision-threatening CMVR.